TrialCirculation2015

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Erin A Bohula et al.PubMed ↗Publisher ↗

No numbers read from the abstract.